STRASBOURG, France--(EON: Enhanced Online News)--Regulatory News:
“Local and abscopal effects in oncolytic virotherapy are boosted by immune checkpoint blockade, immunogenic chemotherapy, or IFNAR blockade”
Transgene (Paris:TNG), a biotechnology company focused on designing and developing viral-based immune-targeted therapies for the treatment of cancers and infectious diseases, announces today that it will present a poster with new and encouraging preclinical data of a next generation armed engineered oncolytic virus at the American Association for Cancer Research annual meeting in Washington, DC.
This immunological data further support the development of armed oncolytic viruses that have the capacity to modulate the tumor micro-environment and improve T-cell infiltration in the tumor.
- The next generation Oncolytic Virus (OV) demonstrated its ability to induce complete response in the primary tumor and immune-mediated regression of distant metastases;
- This Oncolytic Virus induced immunogenic tumor cell death and generated a systemic immune response. This response is associated with an increase of cytotoxic CD8+ T cells infiltration (particularly PD-1+ CD8+ T cells) and a decrease of regulatory T-cells in the tumor;
- The therapeutic activity of this next generation Oncolytic Virus was further enhanced when combined with either chemotherapy or with immune checkpoint inhibitor (ICI) such as anti-PD-1 or anti-CTLA-4.
The poster entitled “Local and abscopal effects in oncolytic virotherapy are boosted by immune checkpoint blockade, immunogenic chemotherapy, or IFNAR blockade” will be presented on Tuesday, April 4th, from 1:00 to 5:00 pm EST in the section 25. The abstract is available on the AACR website.
The poster presents preclinical results of a modified vaccinia virus expressing the Fcu1 gene (VVWR-TK-RR--Fcu1), which is able to transform the non-cytotoxic pro-drug, flucytosine (5-FC), into 5-FU, a widely used cancer chemotherapy. Results show that this next generation armed oncolytic virus is able to induce an immunogenic cell death and thus to generate a systemic immune response in immuno-competent mouse models.
These preclinical data further strengthen the preclinical data package of Transgene’s most advanced next generation oncolytic virus, TG6002. TG6002 is due to enter the clinic in H1 2017 in patients with recurrent glioblastoma.
Transgene S.A. (Euronext: TNG), part of Institut Mérieux, is a publicly traded French biopharmaceutical company focused on designing and developing targeted immunotherapies for the treatment of cancer and infectious diseases. Transgene’s programs utilize viral vector technology with the goal of indirectly or directly killing infected or cancerous cells. The Company’s two lead clinical-stage programs are: TG4010, a therapeutic vaccine for non-small cell lung cancer and Pexa-Vec, an oncolytic virus for liver cancer. The Company has several other programs in clinical and preclinical development. Transgene is based in Strasbourg, France, and has additional operations in Lyon, as well as a joint venture in China. Additional information about Transgene is available at www.transgene.fr.
Follow us on Twitter: @TransgeneSA
This press release contains forward-looking statements, which are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. The occurrence of any of these risks could have a significant negative outcome for the Company’s activities, perspectives, financial situation, results, regulatory authorities’ agreement with development phases, and development. The Company’s ability to commercialize its products depends on but is not limited to the following factors: positive pre-clinical data may not be predictive of human clinical results, the success of clinical studies, the ability to obtain financing and/or partnerships for product manufacturing, development and commercialization, and marketing approval by government regulatory authorities. For a discussion of risks and uncertainties which could cause the Company’s actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors (“Facteurs de Risque”) section of the Document de Référence, available on the AMF website (http://www.amf-france.org) or on Transgene’s website (www.transgene.fr). Forward-looking statements speak only as of the date on which they are made and Transgene undertakes no obligation to update these forward-looking statements, even if new information becomes available in the future.